<DOC>
	<DOCNO>NCT02787642</DOCNO>
	<brief_summary>A phase Ib study Olaparib concomitant radiotherapy locally advanced/unresectable soft-tissue sarcoma .</brief_summary>
	<brief_title>A Study Olaparib With Concomitant Radiotherapy Locally Advanced/Unresectable Soft-tissue Sarcoma</brief_title>
	<detailed_description>This multicenter , prospective phase Ib trial base dose escalation study design ( 3+3 traditional design ) assess four dose level Olaparib give concomitant radiotherapy , follow expansion cohort .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>1 . Histology : patient softtissue sarcoma histologically confirmed central review ( Pr Coindre team ) , except diagnosis already confirm RRePS Network , 2 . Upper/Lower limb trunk wall softtissue sarcoma , 3 . Age ≥ 18 year , 4 . Locally advanced locally recurrent inoperable tumor , outside previously irradiated field ( inoperable status must assess staff include surgeon specialize sarcoma ) , 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 , 6 . Life expectancy ≥ 6 month , 7 . At least one lesion , previously irradiate , accurately measure baseline ≥ 10 mm long diameter ( except lymph node must short axis ≥ 15 mm ) magnetic resonance imaging ( MRI ) suitable accurate repeat measurement , 8 . Adequate hematological , renal , metabolic hepatic function : Haemoglobin ≥ 9 g/dL blood transfusion 14 day prior study entry Absolute neutrophil count ( ANc ) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Total bilirubin ≤ 1.5 x upper limit normality ( ULN ) , Alanine aminotransferase ( ALAT ) aspartate aminotransferase ( ASAT ) ≤ 2.5 x ULN , Serum creatinine ≤ 150 μmol/L creatinine clearance ≥ 50 mL/min ( accord local institution ) case serum creatinine &gt; 150 μmol/L , TP , INR ≤ 1.5 x ULN 9 . Women childbearing potential must negative serum pregnancy test within 28 day study treatment , confirm prior treatment day 1 . Female patient child bear potential partner , sexually active , must agree use two highly effective form contraception combination throughout period take study treatment least 1 month last dose study drug . Males patient , sexually active , must agree use two highly effective form contraception combination throughout period take study treatment least 3 month last dose study drug . Acceptable birth control method describe appendix 10 . Subjects nonchildbearing potential : Amenorrheic 1 year follow cessation exogenous hormonal treatment , LH FSH level post menopausal range woman 50 , radiationinduced oophorectomy last menses &gt; 1 year ago , chemotherapyinduced menopause &gt; 1 year interval since last menses , surgical sterilisation ( bilateral oophorectomy hysterectomy ) . 10 . Patient willing able comply protocol duration study include undergoing treatment schedule visit examination include follow , 11 . Voluntary sign dated write informed consent prior specific procedure , 12 . Patients French social security compliance Law relate biomedical research ( Article L.112111 French Public Health Code ) . 1 . Any previous treatment PARP inhibitor , include Olaparib , 2 . Patients unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication , 3 . Immunocompromised patient , e.g. , patient know serologically positive human immunodeficiency virus ( HIV ) receive antiviral therapy , 4 . Patients know active hepatic disease ( i.e. , Hepatitis B C ) due risk transmit infection blood body fluid , 5 . Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 3 month ) myocardial infarction , unstable spinal cord compression ( untreated unstable least 28 day prior study entry ) , superior vena cava syndrome , extensive bilateral lung disease HRCT scan psychiatric disorder prohibits obtain informed consent , 6 . Patients uncontrolled seizure , 7 . Men woman childbearing potential use effective method contraception previously describe ; woman pregnant breast feeding , 8 . No prior concurrent malignant disease diagnose treat last 2 year , except adequately treat situ carcinoma cervix , basal squamous skin cell carcinoma , situ transitional bladder cell carcinoma , 9 . Patients receive systemic chemotherapy within 2 week last dose prior study treatment ( long period depend defined characteristic agent use ) , 10 . Concomitant use know CYP3A4 inhibitor ketokonazole , itraconazole , ritonavir , indinavir , saquinavir , telithromycin , clarithromycin nelfinavir , 11 . Resting ECG QTc &gt; 470msec 2 time point within 24 hour period family history long QT syndrome , 12 . Blood transfusion within 14 day prior study start , 13 . Patients myelodysplastic syndrome/acute myeloid leukaemia , 14 . Major surgery within 14 day start study treatment patient must recover effect major surgery , 15 . Participation study involve medical therapeutic intervention last 30 day , 16 . Patient unable follow comply study procedure geographical , familial , social psychological reason , 17 . Previous enrollment present study , 18 . Patients know hypersensitivity olaparib excipients product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced soft-tissue sarcoma</keyword>
	<keyword>Unresectable Soft-tissue Sarcoma</keyword>
</DOC>